Investor Relations

Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.

Stock Information
ASND (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Up 6.50 (23.43%)
Data as of 09/22/17 4:00 p.m. ET
Refresh quote
Stock chart for: ASND.O.  Currently trading at $34.24 with a 52 week high of $31.86 and a 52 week low of $17.15.
Recent NewsMore >>
Ascendis Pharma A/S Announces Presentations on Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences
Ascendis Pharma A/S Reports Second Quarter 2017 Financial Results
Ascendis Pharma A/S Announces Upcoming Investor Presentations
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Scott T. Smith
Chief Financial Officer
Ascendis Pharma

Data provided by Nasdaq. Minimum 15 minutes delayed.